Sarepta Therapeutics

SRPT

Market cap $2.28B

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in the first quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.

SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery potential.

Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged almost 26% to about $22 after the biotechnology company shared early clinical results from two of its investigational siRNA therapies for neuromuscular diseases, showing dose-dependent muscle exposure and favorable tolerability. Phase 1/2 studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated that the αvβ6 integrin-targeted delivery platform achieved high concentrations in muscle tissue without dose-limiting toxicity.

Sarepta Therapeutics recently shared the first clinical results from its siRNA programs, specifically SRP-1001 and SRP-1003, which are designed to treat facioscapulohumeral muscular dystrophy (FSHD1) and myotonic dystrophy type 1 (DM1), respectively.

The fear gauge pulled back on Wednesday. The CBOE Volatility Index, better known as the VIX, is trading near 25.6 this morning, a drop of roughly 5% from Tuesday's close of 26.95, as geopolitical optimism and a sharp pullback in oil prices sent investors back into equities.